Role of transforming growth factor-β in inflammatory bowel disease and colitis-associated colon cancer

Inflammatory Bowel Diseases

Volumn 16, Issue 11, 2010, Pages 1963-1968

  Feagins, Linda A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

cancer risk; carcinogenesis; chronic inflammation; inflammatory bowel disease; transforming growth factor

Indexed keywords

BOSWELLIA SERRATA EXTRACT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; RECOMBINANT VACCINE; SCUTELLARIA BAICALENSIS EXTRACT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CANCER RISK; CARCINOGENESIS; CHRONIC INFLAMMATION; COLITIS; COLORECTAL CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; EFFECTOR CELL; ENTERITIS; HUMAN; IMMUNOREGULATION; INTESTINAL FIBROSIS; INTESTINE OBSTRUCTION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; ULCERATIVE COLITIS;

ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLITIS; COLONIC NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE ACTIVATION; MICE; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 78249231410     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21281     Document Type: Review

References (61)

1. Zhang HY, Spechler SJ, Souza RF,. Esophageal adenocarcinoma arising in Barretts esophagus. Cancer Lett. 2008; 275: 170-177.
2. McKay CJ, Glen P, McMillan DC,. Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol. 2008; 22: 65-73.
3. Genta RM,. The gastritis connection: prevention and early detection of gastric neoplasms. J Clin Gastroenterol. 2003; 36 (suppl 5): 44-49.
4. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459.
5. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133: 1099-1105.
6. Canavan C, Abrams KR, Mayberry J,. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohns disease. Aliment Pharmacol Ther. 2006; 23: 1097-1104.
7. Roessner A, Kuester D, Malfertheiner P, et al. Oxidant stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract. 2008; 204: 511-524.
8. Feagins LA, Souza RF, Spechler SJ,. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol. 2009; 6: 297-305.
9. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK,. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 4280-4288.
10. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118: 285-296.
11. Wirtz S, Neurath MF,. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev. 2007; 59: 1073-1083.
12. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009; 361: 2033-2045.
13. Sturlan S, Oberhuber G, Beinhauer BG, et al. Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis. 2001; 22: 665-671.
14. Mayer L, Dotan I,. Immune cell-epithelial cell interactions. In:, Sartor RB, Sandborn WJ, eds. Kirsners inflammatory bowel diseases, 6th ed. Edinburgh: Saunders; 2004: 46-59.
15. Shi Y, Massagué J,. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113: 685-700.
16. Massagué J,. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000; 1: 169-178.
17. Massagué J, Chen YG,. Controlling TGF-beta signaling. Genes Dev. 2000; 14: 627-644.
18. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992; 359: 693-699.
19. Kulkarni AB, Ward JM, Yaswen L, et al. Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am J Pathol. 1995; 146: 264-275.
20. Gorelik L, Flavell RA,. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000; 12: 171-181.
21. Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 1999; 18: 1280-1291.
22. Di Sabatino A, Pickard KM, Rampton D, et al. Blockade of transforming growth factor beta upregulates T-box transcription factor T-beta, and increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa. Gut. 2008; 57: 605-612.
23. Babyatsky MW, Rossiter G, Podolsky DK,. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology. 1996; 110: 975-984.
24. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001; 108: 601-609.
25. Monteleone G, Del Vecchio Blanco G, Monteleone I, et al. Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology. 2005; 129: 1420-1429.
26. H-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007; 8: 345-350.
27. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434.
28. H17 and regulatory T cells. Nature. 2006; 441: 235-238.
29. H17 lineage. Nature. 2006; 441: 231-234.
30. Burke JP, Mulsow JJ, O'Keane C, et al. Fibrogenesis in Crohns disease. Am J Gastroenterol. 2007; 102: 439-448.
31. Lawrance IC, Maxwell L, Doe W,. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis. 2001; 7: 16-26.
32. Mulsow JJ, Watson RW, Fitzpatrick JM, et al. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg. 2005; 242: 880-887.
33. Regan MC, Flavin BM, Fitzpatrick JM, et al. Stricture formation in Crohns disease: the role of intestinal fibroblasts. Ann Surg. 2000; 231: 46-50.
34. Ma Y, Guan Q, Bai A, et al. Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis. Inflamm Bowel Dis. 2009 [Epub ahead of print].
35. Latella G, Vetuschi A, Sferra R, et al. Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis. Eur J Clin Invest. 2009; 39: 145-156.
36. Wengrower D, Zanninelli G, Pappo O, et al. Prevention of fibrosis in experimental colitis by captopril: the role of tgf-beta1. Inflamm Bowel Dis. 2004; 10: 536-545.
37. Koga H, Yang H, Adler J, et al. Transanal delivery of angiotension converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: development of a unique mode of treatment. Surgery. 2008; 144: 259-268.
38. Latella G, Sferra R, Vetuschi A, et al. Prevention of colonic fibrosis by Botwellia and Scutellaria extracts in rats with colitis induced by 2,4,5-trinitrobenzene sulphonic acid. Eur J Clin Invest. 2008; 38: 410-420.
39. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell. 2000; 100: 57-70.
40. Elliott RL, Blobe GC,. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005; 23: 2078-2093.
41. Massagué J, Blain SW, Lo RS,. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000; 103: 295-309.
42. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004; 21: 491-501.
43. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995; 268: 1336-138.
44. Souza RF, Lei J, Yin J, et al. A transforming growth factor β1 receptor type II mutation in ulcerative colitis-associated neoplasms. Gastroenterology. 1997; 112: 40-45.
45. Fujiwara I, Yashiro M, Kubo N, et al. Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. Dis Colon Rectum. 2008; 51: 1387-1394.
46. Wang D, Kanuma T, Mizunuma H, et al. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. Cancer Res. 2000; 60: 4507-4512.
47. Ku JL, Park SH, Yoon KA, et al. Genetic alterations of the TGF-beta signaling pathway in colorectal cancer cell lines: a novel mutation in Smad3 associated with the inactivation of TGF-beta-induced transcriptional activation. Cancer Lett. 2007; 247: 283-292.
48. Xu Y, Pasche B,. TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet. 2007; 16 (Spec No 1): R14-20.
49. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 1998; 280: 1086-1088.
50. Miyaki M, Iijima T, Konishi M, et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene. 1999; 18: 3098-3103.
51. Hachimine D, Uchida K, Asada M, et al. Involvement of Smad3 phosphoisoform-mediated signaling in the development of colonic cancer in IL-10-deficient mice. Int J Oncol. 2008; 32: 1221-1226.
52. Friedman E, Gold LI, Klimstra D, et al. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev. 1995; 4: 549-554.
53. Daniel P, Wagrowska-Danilewicz M, Danilewicz M, et al. Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma. Int J Colorectal Dis. 2007; 22: 1165-1172.
54. Reiss M, Barcellos-Hoff MH,. Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat. 1997; 45: 81-95.
55. Shirai Y, Kawata S, Tamura S, et al. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer. 1994; 73: 2275-2279.
56. Bedossa P, Peltier E, Terris B, et al. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology. 1995; 21: 760-766.
57. Reed JA, McNutt NS, Prieto VG, et al. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol. 1994; 145: 97-104.
58. Zhang B, Halder SK, Zhang S, et al. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett. 2009; 277: 114-120.
59. Becker C, Fantini MC, Neurath MF,. TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev. 2006; 17: 97-106.
60. Chen ML, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A. 2005; 102: 419-424.
61. Fichtner-Feigl S, Terabe M, Kitani A, et al. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res. 2008; 68: 3467-3475.